According to the HFA-ICOS score, risk factors for anti-HER2 therapies include older age, pre-existing CVD, previous or concurrent anthracycline use, prior radiotherapy to left chest or mediastinum, obesity, hypertension and diabetes mellitus (DM)[9]. This evidence concerns the gene ERBB2 and diabetes mellitus.